A small population of CD44+/CD24−/low cells were originally isolated from patient tumors in 2003 by Al-Hajj et al., in which these cells were found to have high tumor-initiating potential, 10- to 50-fold greater than CD44+/CD24+ cells, when injected into immune-compromised mice. This evidence concerns the gene CD44 and neoplasm.